trial

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCTId NCT03896945
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 136 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-05-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
136 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-02-15
Primary completion
2023-05-23
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
AVP-786

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

72 total
Little Rock, United StatesAnaheim, United StatesBellflower, United StatesCosta Mesa, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLa Habra, United StatesLafayette, United StatesLemon Grove, United StatesOakland, United StatesOceanside, United States

Linked catalysts

1
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symp — primary completion2023-05-23

Facts & assertions

4 sourced
Enrollment
136
Phase
PHASE2,PHASE3
Primary Completion Date
2023-05-23
Status
TERMINATED
relationships
The graph out of here
drug
AVP-786
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication